Global Varicella Attenuated Live Vaccine Market Size, Share, Trends and Forecast 2022-2030

Description

Market Analysis and Insights: Global Varicella Attenuated Live Vaccine Market
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

Due to the COVID-19 pandemic, the global Varicella Attenuated Live Vaccine market size is estimated to be worth US$ 2672.7 million in 2022 and is forecast to a readjusted size of US$ 3440.8 million by 2028 with a CAGR of 4.3% during the review period. Fully considering the economic change by this health crisis, Monovalent Vaccine accounting for % of the Varicella Attenuated Live Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Kids Injection segment is altered to an % CAGR throughout this forecast period.

For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.

The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.

Market Segments

The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

Segment by Type

Monovalent Vaccine

Combination Vaccine

Segment by Application

Kids Injection

Adults Injection

Consequence of Covid-19 Pandemic

The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the Varicella Attenuated Live Vaccine market back to the pre-covid levels.

Trends & Prospects

In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

Competitive Outlook

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and share analysis of the prominent players are also provided in this section. They have also provided reliable sales and revenue data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

Merck

BCHT

Shanghai Institute

GSK

Keygen

Green Cross

Biken

Shanghai Rongsheng Biotech

Changchun Changsheng Life Sciences Limited

TABLE OF CONTENT

1 Study Coverage
1.1 Varicella Attenuated Live Vaccine Product Introduction

1.2 Market by Type

1.2.1 Global Varicella Attenuated Live Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Monovalent Vaccine

1.2.3 Combination Vaccine

1.3 Market by Application

1.3.1 Global Varicella Attenuated Live Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Kids Injection

1.3.3 Adults Injection

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts 2017-2028

2.2 Global Varicella Attenuated Live Vaccine Revenue Estimates and Forecasts 2017-2028

2.3 Global Varicella Attenuated Live Vaccine Revenue by Region: 2017 VS 2021 VS 2028

2.4 Global Varicella Attenuated Live Vaccine Sales by Region

2.4.1 Global Varicella Attenuated Live Vaccine Sales by Region (2017-2022)

2.4.2 Global Sales Varicella Attenuated Live Vaccine by Region (2023-2028)

2.5 Global Varicella Attenuated Live Vaccine Revenue by Region

2.5.1 Global Varicella Attenuated Live Vaccine Revenue by Region (2017-2022)

2.5.2 Global Varicella Attenuated Live Vaccine Revenue by Region (2023-2028)

2.6 North America

2.7 Europe

2.8 Asia-Pacific

2.9 Latin America

2.10 Middle East & Africa

3 Competition by Manufacturers

3.1 Global Varicella Attenuated Live Vaccine Sales by Manufacturers

3.1.1 Global Top Varicella Attenuated Live Vaccine Manufacturers by Sales (2017-2022)

3.1.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Manufacturers (2017-2022)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Varicella Attenuated Live Vaccine in 2021

3.2 Global Varicella Attenuated Live Vaccine Revenue by Manufacturers

3.2.1 Global Varicella Attenuated Live Vaccine Revenue by Manufacturers (2017-2022)

3.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Manufacturers (2017-2022)

3.2.3 Global Top 10 and Top 5 Companies by Varicella Attenuated Live Vaccine Revenue in 2021

3.3 Global Varicella Attenuated Live Vaccine Sales Price by Manufacturers (2017-2022)

3.4 Analysis of Competitive Landscape

3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4.3 Global Varicella Attenuated Live Vaccine Manufacturers Geographical Distribution

3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Varicella Attenuated Live Vaccine Sales by Type

4.1.1 Global Varicella Attenuated Live Vaccine Historical Sales by Type (2017-2022)

4.1.2 Global Varicella Attenuated Live Vaccine Forecasted Sales by Type (2023-2028)

4.1.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2017-2028)

4.2 Global Varicella Attenuated Live Vaccine Revenue by Type

4.2.1 Global Varicella Attenuated Live Vaccine Historical Revenue by Type (2017-2022)

4.2.2 Global Varicella Attenuated Live Vaccine Forecasted Revenue by Type (2023-2028)

4.2.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2017-2028)

4.3 Global Varicella Attenuated Live Vaccine Price by Type

4.3.1 Global Varicella Attenuated Live Vaccine Price by Type (2017-2022)

4.3.2 Global Varicella Attenuated Live Vaccine Price Forecast by Type (2023-2028)

5 Market Size by Application

5.1 Global Varicella Attenuated Live Vaccine Sales by Application

5.1.1 Global Varicella Attenuated Live Vaccine Historical Sales by Application (2017-2022)

5.1.2 Global Varicella Attenuated Live Vaccine Forecasted Sales by Application (2023-2028)

5.1.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2017-2028)

5.2 Global Varicella Attenuated Live Vaccine Revenue by Application

5.2.1 Global Varicella Attenuated Live Vaccine Historical Revenue by Application (2017-2022)

5.2.2 Global Varicella Attenuated Live Vaccine Forecasted Revenue by Application (2023-2028)

5.2.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2017-2028)

5.3 Global Varicella Attenuated Live Vaccine Price by Application

5.3.1 Global Varicella Attenuated Live Vaccine Price by Application (2017-2022)

5.3.2 Global Varicella Attenuated Live Vaccine Price Forecast by Application (2023-2028)

6 North America

6.1 North America Varicella Attenuated Live Vaccine Market Size by Type

6.1.1 North America Varicella Attenuated Live Vaccine Sales by Type (2017-2028)

6.1.2 North America Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)

6.2 North America Varicella Attenuated Live Vaccine Market Size by Application

6.2.1 North America Varicella Attenuated Live Vaccine Sales by Application (2017-2028)

6.2.2 North America Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)

6.3 North America Varicella Attenuated Live Vaccine Market Size by Country

6.3.1 North America Varicella Attenuated Live Vaccine Sales by Country (2017-2028)

6.3.2 North America Varicella Attenuated Live Vaccine Revenue by Country (2017-2028)

6.3.3 U.S.

6.3.4 Canada

7 Europe

7.1 Europe Varicella Attenuated Live Vaccine Market Size by Type

7.1.1 Europe Varicella Attenuated Live Vaccine Sales by Type (2017-2028)

7.1.2 Europe Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)

7.2 Europe Varicella Attenuated Live Vaccine Market Size by Application

7.2.1 Europe Varicella Attenuated Live Vaccine Sales by Application (2017-2028)

7.2.2 Europe Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)

7.3 Europe Varicella Attenuated Live Vaccine Market Size by Country

7.3.1 Europe Varicella Attenuated Live Vaccine Sales by Country (2017-2028)

7.3.2 Europe Varicella Attenuated Live Vaccine Revenue by Country (2017-2028)

7.3.3 Germany

7.3.4 France

7.3.5 U.K.

7.3.6 Italy

7.3.7 Russia

8 Asia Pacific

8.1 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Type

8.1.1 Asia Pacific Varicella Attenuated Live Vaccine Sales by Type (2017-2028)

8.1.2 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)

8.2 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Application

8.2.1 Asia Pacific Varicella Attenuated Live Vaccine Sales by Application (2017-2028)

8.2.2 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)

8.3 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Region

8.3.1 Asia Pacific Varicella Attenuated Live Vaccine Sales by Region (2017-2028)

8.3.2 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Region (2017-2028)

8.3.3 China

8.3.4 Japan

8.3.5 South Korea

8.3.6 India

8.3.7 Australia

8.3.8 Taiwan

8.3.9 Indonesia

8.3.10 Thailand

8.3.11 Malaysia

8.3.12 Philippines

9 Latin America

9.1 Latin America Varicella Attenuated Live Vaccine Market Size by Type

9.1.1 Latin America Varicella Attenuated Live Vaccine Sales by Type (2017-2028)

9.1.2 Latin America Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)

9.2 Latin America Varicella Attenuated Live Vaccine Market Size by Application

9.2.1 Latin America Varicella Attenuated Live Vaccine Sales by Application (2017-2028)

9.2.2 Latin America Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)

9.3 Latin America Varicella Attenuated Live Vaccine Market Size by Country

9.3.1 Latin America Varicella Attenuated Live Vaccine Sales by Country (2017-2028)

9.3.2 Latin America Varicella Attenuated Live Vaccine Revenue by Country (2017-2028)

9.3.3 Mexico

9.3.4 Brazil

9.3.5 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Type

10.1.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Type (2017-2028)

10.1.2 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)

10.2 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Application

10.2.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Application (2017-2028)

10.2.2 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)

10.3 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country

10.3.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2017-2028)

10.3.2 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Country (2017-2028)

10.3.3 Turkey

10.3.4 Saudi Arabia

11 Company Profiles

11.1 Merck

11.1.1 Merck Corporation Information

11.1.2 Merck Overview

11.1.3 Merck Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.1.4 Merck Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 Merck Recent Developments

11.2 BCHT

11.2.1 BCHT Corporation Information

11.2.2 BCHT Overview

11.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.2.4 BCHT Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 BCHT Recent Developments

11.3 Shanghai Institute

11.3.1 Shanghai Institute Corporation Information

11.3.2 Shanghai Institute Overview

11.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 Shanghai Institute Recent Developments

11.4 GSK

11.4.1 GSK Corporation Information

11.4.2 GSK Overview

11.4.3 GSK Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.4.4 GSK Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 GSK Recent Developments

11.5 Keygen

11.5.1 Keygen Corporation Information

11.5.2 Keygen Overview

11.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.5.4 Keygen Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 Keygen Recent Developments

11.6 Green Cross

11.6.1 Green Cross Corporation Information

11.6.2 Green Cross Overview

11.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.6.4 Green Cross Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 Green Cross Recent Developments

11.7 Biken

11.7.1 Biken Corporation Information

11.7.2 Biken Overview

11.7.3 Biken Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.7.4 Biken Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 Biken Recent Developments

11.8 Shanghai Rongsheng Biotech

11.8.1 Shanghai Rongsheng Biotech Corporation Information

11.8.2 Shanghai Rongsheng Biotech Overview

11.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.8.5 Shanghai Rongsheng Biotech Recent Developments

11.9 Changchun Changsheng Life Sciences Limited

11.9.1 Changchun Changsheng Life Sciences Limited Corporation Information

11.9.2 Changchun Changsheng Life Sciences Limited Overview

11.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.9.5 Changchun Changsheng Life Sciences Limited Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Varicella Attenuated Live Vaccine Industry Chain Analysis

12.2 Varicella Attenuated Live Vaccine Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Varicella Attenuated Live Vaccine Production Mode & Process

12.4 Varicella Attenuated Live Vaccine Sales and Marketing

12.4.1 Varicella Attenuated Live Vaccine Sales Channels

12.4.2 Varicella Attenuated Live Vaccine Distributors

12.5 Varicella Attenuated Live Vaccine Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

13.1 Varicella Attenuated Live Vaccine Industry Trends

13.2 Varicella Attenuated Live Vaccine Market Drivers

13.3 Varicella Attenuated Live Vaccine Market Challenges

13.4 Varicella Attenuated Live Vaccine Market Restraints

14 Key Findings in The Global Varicella Attenuated Live Vaccine Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

Choose License Type

Checkout Inquiry Sample